Trial Profile
A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2020
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 07 May 2019 Status changed from active, no longer recruiting to completed.
- 11 Apr 2018 Results assessing safety and efficacy published in the Journal of Clinical Oncology
- 06 Mar 2018 Planned End Date changed from 1 Aug 2021 to 1 Aug 2022.